Navigation Links
SCOLR Pharma Welcomes Clem Calabrese as Director of Field Sales

BELLEVUE, Wash., May 1, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that effective May 1, 2012 Clem Calabrese will be joining the SCOLR team as Director of Field Sales to lead our aggressive field sales & marketing activities.  Clem brings a wealth of field sales experience to SCOLR and will be primarily responsible for working with our existing sales staff, the Emerson Group and our retail customers in order to ensure we aggressively grow our sales while providing the utmost in customer service.

Clem brings over 35 years of Branded and Store Brand Sales & Marketing experience with Major Consumer Products Companies.

Stephen Turner, President and CEO of SCOLR, said: "We are excited to have Clem join the SCOLR team.  He is an impressive individual and will most assuredly provide us with additional sales opportunities as we continue to grow our consumer products sales.  The depth of his relationships and contacts within the industry will enable SCOLR to continue the momentum created with our CDT® Controlled Release Technology with retailers."

About SCOLR Pharma:

Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit

Forward looking statements:                                              

Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward looking statements include statements regarding SCOLR's partners development of drug formulations, the results of a bioequivalence trials, anticipated future plans related to approval of drug formulations by the Food and Drug Administration, and the development and marketing of any drug formulations.  Factors that could cause these forward-looking statements to differ from actual results include adverse regulatory determinations related to trials, competitive factors related to drug products, economic factors including partner's ability to finance the development and commercialization of any product, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission.  SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Investor Relations:                                             
SCOLR Pharma, Inc.                                            

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Provides Product Information on Website
2. SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012
3. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
4. SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products
5. SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
6. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
7. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
8. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
9. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
10. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
11. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
Post Your Comments:
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
(Date:11/30/2015)... , Nov. 30, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic pain, ... at the U.S. Patent and Trademark Office (USPTO) has denied ... Patent No. 8,359,102 (the ,102 patent).  ... unit of Boston Scientific Corporation filed two petitions challenging the ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal ... announced the launch of Radiology Solutions, a fully ... Radiology Solutions comprises customized, data-driven practice management approaches ... to help radiology practices improve care delivery and ... 2015 Radiological Society of North America Annual Meeting ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase awareness of the lack of standards ... inform dentists that the technicians they trust could lack the skills and knowledge ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... The directory is specialized and only includes chiropractic clinics in the US. , ... and trustworthy alternative health practitioner when back pain sets in. When people are ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... experience this summer, ushering in a new era of publicly accessible automated technology. ... shuttle, will continue to offer guests an up-close look at the shuttle at ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... for Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted ... featuring a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort ... to access life-saving information provided directly from top experts in mesothelioma, in ... individual conferences in three major cities: Houston, San Francisco, and Chicago. , ...
Breaking Medicine News(10 mins):